What question did this study set out to answer?

Evaluate clinical features and chemotherapy outcomes in adult lymphoma patients treated at Jimma University Medical Center.

March 27, 2026Open Access

Clinical Profile and Chemotherapy Outcomes of Adult Lymphoma Patients at Jimma University Medical Center: A 2‐Year Retrospective Study

Key Points

Evaluate clinical features and chemotherapy outcomes in adult lymphoma patients treated at Jimma University Medical Center.
Retrospective review of patient records from April 2022 to March 2024.
Data collection using structured questionnaires to capture demographics, clinical findings, and outcomes.
Descriptive statistics for analyzing frequencies and proportions.
85% of the patients had non-Hodgkin lymphoma, while 15% had Hodgkin lymphoma.
Common symptoms included lymphadenopathy in 47.8% and B symptoms in 42.0%.
Complete remission rates were 60% for Hodgkin lymphoma and 49.7% for non-Hodgkin lymphoma.

Abstract

ABSTRACT Background Lymphoma, including Hodgkin (HL) and non‐Hodgkin (NHL) subtypes, is a leading non‐infectious cause of morbidity and mortality in Ethiopia. Diagnosis relies on histopathology with immunohistochemistry or flow cytometry; staging and prognosis use laboratory tests and imaging. Treatment selection depends on subtype, stage, and resources. This study evaluated clinical features and chemotherapy outcomes among adult lymphoma patients at Jimma University Specialized Hospital Oncology Unit. Method An institution‐based retrospective review of patients treated from April 2022 to March 2024 was performed. Data were abstracted from September to November 2024 using a structured questionnaire capturing socio‐demographics, clinical and histopathological findings, treatment regimens, and outcomes. Descriptive statistics summarized frequencies and proportions; results are presented in tables and graphs. Result: Among 197 patients, 85% had NHL and 15% HL. NHL predominated in older adults (43.7% aged 46–60); HL clustered in younger patients (66.7% aged 15–30). Male predominance was observed in both subtypes. High‐grade histology occurred in 62.9% of NHL; mixed cellularity was the commonest HL subtype (36.7%). Most presented at Stage 2 (37.6%) or Stage 3 (36.5%); head and neck nodal disease (30.1%) and extranodal involvement (45.2%), mainly spleen, were frequent. Lymphadenopathy (47.8%) and B symptoms (42.0%) were common; hypertension was the leading comorbidity (56.6%). Elevated LDH was frequent in both groups (∼90%). All HL patients received ABVD; 83.8% of NHL patients received CHOP, and 94.4% completed six cycles. Complete remission rates were 60% for HL and 49.7% for NHL; 11.7% required second‐line therapy. Conclusion NHL predominates in older adults while HL affects younger patients. Late intermediate‐stage presentation, high comorbidity burden, and limited access to targeted agents likely contributed to lower remission in NHL, highlighting the need for earlier diagnosis, risk stratification, and resource‐appropriate treatment optimization. Trial Registration The authors have confirmed clinical trial registration is not needed for this submission.

Read Full Paperexternally

AIに質問

Bookmark

View Full Paper